How Much Weight Can You Lose with Compounded Semaglutide?

Last reviewed: June 8, 2026

Last updated: June 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

There is no published weight-loss figure for compounded semaglutide, because compounded preparations are not studied in randomised trials. The numbers people quote all come from the approved brand programmes: in Wegovy Study 2, a 68-week trial of 1,961 patients, mean body weight change was −14.9% with semaglutide injection versus −2.4% with placebo, according to the Wegovy prescribing information. Whether a compounded preparation performs comparably has not been demonstrated, and the FDA states that it does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.

What the Approved-Product Trials Reported

Wegovy Study 2 enrolled 1,961 patients with obesity, defined as body mass index of 30 kg/m² or greater, or with overweight at 27 to 29.9 kg/m² plus at least one weight-related comorbid condition such as treated or untreated dyslipidemia or hypertension. Type 2 diabetes was an exclusion. Mean change in body weight at 68 weeks was −14.9% versus −2.4% with placebo, a difference of −12.4 percentage points.

Study 4, over the same 68 weeks but paired with intensive lifestyle therapy, reported −16% versus −5.7%. Study 3, in 807 patients with type 2 diabetes and body mass index of at least 27 kg/m², reported −9.6% versus −3.4%.

Study 8, a 72-week trial in 1,407 patients with obesity, tested a 7.2 mg dosage against 2.4 mg and placebo and is the basis for the higher labeled maximum now in the Wegovy label. Every one of these figures belongs to an FDA-approved product tested under protocol.

Why Those Numbers Do Not Transfer Automatically

A compounded preparation is not the approved product. The FDA states that compounded drugs are not FDA-approved and that the agency does not verify their safety, effectiveness or quality before marketing. It further states that compounded drugs and generic drugs are not the same: a generic is approved under section 505(j) and must establish therapeutic equivalence to a brand product, while a compounded drug is not approved at all.

That distinction matters directly here. Therapeutic equivalence is the regulatory mechanism by which trial results are allowed to transfer from one product to another. Compounded preparations do not go through it.

The FDA has additionally reported that some semaglutide products sold by compounders may be salt forms such as semaglutide sodium or semaglutide acetate, which the agency describes as different active ingredients than those used in the approved drugs, with unknown comparability of chemical and pharmacologic properties.

The Averages Conceal Enormous Individual Variation

Even within the approved-product trials, the group mean is a poor description of any individual result. That is why the labels report the proportions of participants achieving 5%, 10% and 15% weight loss rather than the average alone — the distribution is wide in both directions.

Trial conditions also differ from ordinary life in a way that inflates comparability problems. Participants in the Wegovy programme received instruction for an approximately 500 kcal per day deficit and counselling toward a minimum of 150 minutes of physical activity per week, delivered from the first dose and continued throughout.

Adherence Is the Largest Real-World Variable

Recent reviews report that a substantial share of GLP-1 receptor agonist users discontinue within a year of initiation. Discontinuation ends the effect, and randomised withdrawal trials show that roughly two-thirds of lost weight is typically regained within a year of stopping, according to a 2026 review in EClinicalMedicine.

In the trials themselves, discontinuation rates were modest and monitored: in Studies 2, 3 and 4, 16% of Wegovy-treated and 19% of placebo-treated patients discontinued therapy, with 6.8% of Wegovy-treated patients discontinuing due to an adverse reaction. Real-world persistence is lower.

Dosing Errors Are a Documented Risk in This Category

The FDA has received multiple reports of adverse events, some requiring hospitalisation, that may relate to dosing errors with compounded injectable semaglutide — patients measuring and self-administering incorrect doses, and in some cases health care professionals miscalculating doses.

The agency has separately received reports that may relate to patients being prescribed compounded products in doses beyond what appears in the FDA-approved labeling: more product in a single dose, doses taken more frequently, or faster titration. Larger doses are not a route to larger results, and the agency has told prescribers to be vigilant on exactly this point.

How to Set an Honest Expectation

Anchor on the approved-product trial figures as the best available reference, and treat them as group averages produced under structured conditions rather than as a personal forecast. Expect your own trajectory to differ, possibly substantially, in either direction.

Then hold the regulatory distinction clearly: those figures describe Wegovy, an FDA-approved product. A compounded preparation is a different regulatory category prepared by a licensed pharmacy against an individual prescription, and no published trial establishes its weight outcomes.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much weight do people lose on compounded semaglutide?

No randomised trial has measured that. Compounded preparations are not FDA-approved products and are not studied in registration trials. The figures in circulation come from the approved brand programmes: Wegovy Study 2, a 68-week trial in 1,961 patients, reported mean body weight change of minus 14.9% versus minus 2.4% with placebo.

Are compounded and approved semaglutide therapeutically equivalent?

Not as a regulatory matter. The FDA states that compounded drugs and generic drugs are not the same: a generic is approved under section 505(j) of the Act and must establish therapeutic equivalence to a brand product, while a compounded drug is not FDA-approved at all and the agency does not verify its safety, effectiveness or quality before marketing.

Would a higher dose produce more weight loss?

The FDA has reported adverse event reports that may relate to patients being prescribed compounded semaglutide or tirzepatide in doses beyond the approved labeling, including more product per dose, more frequent dosing, or faster titration, and has told providers to be vigilant. Dosing is a prescriber decision governed by response and tolerability, not a lever for accelerating results.

Why do the trial numbers differ so much between studies?

Because the populations and co-interventions differ. Wegovy Study 2 excluded type 2 diabetes and reported minus 14.9%. Study 4 added intensive lifestyle therapy and reported minus 16% against a minus 5.7% placebo arm. Study 3, in patients with type 2 diabetes, reported minus 9.6%. Comparing across studies without matching populations produces misleading conclusions.

What happens to the weight if I stop?

Randomised withdrawal trials across this class consistently show substantial regain after discontinuation, with a 2026 review reporting that roughly two-thirds of lost weight is typically regained within a year of stopping, alongside reversal of some cardiometabolic improvements. Current reviews describe this as recurrence of a chronic relapsing condition rather than as treatment failure.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.